Literature DB >> 9103128

Risk for clinical thromboembolism associated with conversion to sinus rhythm in patients with atrial fibrillation lasting less than 48 hours.

M J Weigner1, T A Caulfield, P G Danias, D I Silverman, W J Manning.   

Abstract

BACKGROUND: It has been assumed that cardioversion in patients with atrial fibrillation lasting less than 48 hours is associated with a low risk for thromboembolism. However, no clinical data support this assumption.
OBJECTIVE: To determine the incidence of cardioversion-related clinical thromboembolism among patients presenting with atrial fibrillation lasting less than 48 hours.
DESIGN: Patients were prospectively identified on admission, and clinical data on the duration of atrial fibrillation were recorded. Data on cardioversion and thromboembolism were obtained retrospectively from hospital and outpatient records.
SETTING: Academic medical center. PATIENTS: 1822 consecutive patients admitted to the hospital for atrial fibrillation were screened. Three hundred seventy-five adults (mean age +/- SD, 68 +/- 16 years) with atrial fibrillation that had lasted less than 48 hours were identified. One hundred eighty-one patients (48.3%) had a history of atrial fibrillation; 23 (6.1%) had a history of thromboembolism.
RESULTS: 357 patients (95.2%) converted to sinus rhythm during the index admission; spontaneous conversion occurred in 250 patients (66.7%) and active pharmacologic or electrical conversion was done in 107 patients (28.5%). Three patients (0.8% [95% CI, 0.2% to 2.4%]), all of whom had converted spontaneously after ventricular rate control was begun, had a clinical thromboembolic event: One had a stroke, 1 had a transient ischemic attack, and 1 had a peripheral embolus. None of these 3 patients had a history of atrial fibrillation or thromboembolism, and all had normal left ventricular systolic function.
CONCLUSION: Among patients presenting with atrial fibrillation that was clinically estimated to have lasted less than 48 hours, the likelihood of cardioversion-related clinical thromboembolism is low. These data support the current recommendation for early cardioversion in these patients.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9103128     DOI: 10.7326/0003-4819-126-8-199704150-00005

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  38 in total

1.  Managing atrial fibrillation in elderly people. What should target international normalised ratio be?

Authors:  T Lancaster
Journal:  BMJ       Date:  1999-08-14

Review 2.  Cardioversion in atrial fibrillation: indications, thromboembolic prophylaxis, and role of transesophageal echocardiography.

Authors:  M L Main; A L Klein
Journal:  J Thromb Thrombolysis       Date:  1999-01       Impact factor: 2.300

Review 3.  Use of oral anticoagulants in older patients.

Authors:  J L Sebastian; D D Tresch
Journal:  Drugs Aging       Date:  2000-06       Impact factor: 3.923

Review 4.  [Electrical and pharmacological strategies for early cardioversion of atrial fibrillation].

Authors:  M Linhart; T Lewalter
Journal:  Herzschrittmacherther Elektrophysiol       Date:  2006-06

Review 5.  Antithrombotic treatment in atrial fibrillation.

Authors:  L Kalra; G Y H Lip
Journal:  Heart       Date:  2006-09-04       Impact factor: 5.994

Review 6.  Acute management of atrial fibrillation with acute haemodynamic instability and in the postoperative setting.

Authors:  C J Mann; S Kendall; G Y H Lip
Journal:  Heart       Date:  2006-09-04       Impact factor: 5.994

7.  Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  John J You; Daniel E Singer; Patricia A Howard; Deirdre A Lane; Mark H Eckman; Margaret C Fang; Elaine M Hylek; Sam Schulman; Alan S Go; Michael Hughes; Frederick A Spencer; Warren J Manning; Jonathan L Halperin; Gregory Y H Lip
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

8.  Incidence of Thromboembolic Complications Within 30 Days of Electrical Cardioversion Performed Within 48 Hours of Atrial Fibrillation Onset.

Authors:  Aatish Garg; Monica Khunger; Sinziana Seicean; Mina K Chung; Patrick J Tchou
Journal:  JACC Clin Electrophysiol       Date:  2016-04-06

9.  Case Study of Fatal Stroke Following Intranasal Lidocaine.

Authors:  Daniel L Moellentin; Dale Stewart; James Barbour
Journal:  Hosp Pharm       Date:  2016-09

Review 10.  Emergency management of atrial fibrillation.

Authors:  A Wakai; J O O'Neill
Journal:  Postgrad Med J       Date:  2003-06       Impact factor: 2.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.